Published in Oncotarget on December 01, 2011
Metformin suppresses growth of human head and neck squamous cell carcinoma via global inhibition of protein translation. Cell Cycle (2012) 1.11
Dual EGFR inhibition in combination with anti-VEGF treatment: a phase I clinical trial in non-small cell lung cancer. Oncotarget (2013) 0.95
A combination of a ribonucleotide reductase inhibitor and histone deacetylase inhibitors downregulates EGFR and triggers BIM-dependent apoptosis in head and neck cancer. Oncotarget (2012) 0.94
Gefitinib resistance resulted from STAT3-mediated Akt activation in lung cancer cells. Oncotarget (2013) 0.91
SPINK1 promotes colorectal cancer progression by downregulating Metallothioneins expression. Oncogenesis (2015) 0.79
Tongue carcinoma infrequently harbor common actionable genetic alterations. BMC Cancer (2014) 0.79
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science (2004) 61.56
KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res (2006) 13.98
Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol (2009) 8.46
Understanding resistance to EGFR inhibitors-impact on future treatment strategies. Nat Rev Clin Oncol (2010) 3.80
Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol (2004) 3.67
Regulation of heparin-binding EGF-like growth factor by miR-212 and acquired cetuximab-resistance in head and neck squamous cell carcinoma. PLoS One (2010) 1.77
Genomic dissection of the epidermal growth factor receptor (EGFR)/PI3K pathway reveals frequent deletion of the EGFR phosphatase PTPRS in head and neck cancers. Proc Natl Acad Sci U S A (2011) 1.21
IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature (2012) 8.66
IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature (2012) 7.95
Genome sequencing identifies a basis for everolimus sensitivity. Science (2012) 6.71
Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med (2015) 5.71
An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science (2013) 5.10
Comparing the DNA hypermethylome with gene mutations in human colorectal cancer. PLoS Genet (2007) 3.39
Comparative genomic analysis of primary versus metastatic colorectal carcinomas. J Clin Oncol (2012) 2.74
Recurrent somatic mutation of FAT1 in multiple human cancers leads to aberrant Wnt activation. Nat Genet (2013) 2.59
Somatic mutations of the Parkinson's disease-associated gene PARK2 in glioblastoma and other human malignancies. Nat Genet (2009) 2.51
Breast cancer methylomes establish an epigenomic foundation for metastasis. Sci Transl Med (2011) 2.33
The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers. Proc Natl Acad Sci U S A (2009) 2.09
Malignancy rate in thyroid nodules classified as Bethesda category III (AUS/FLUS). Thyroid (2014) 2.04
Whole-exome sequencing identifies ATRX mutation as a key molecular determinant in lower-grade glioma. Oncotarget (2012) 2.03
Leptomeningeal metastasis from non-small cell lung cancer: survival and the impact of whole brain radiotherapy. J Thorac Oncol (2012) 1.93
MicroRNA-335 inhibits tumor reinitiation and is silenced through genetic and epigenetic mechanisms in human breast cancer. Genes Dev (2011) 1.85
The mutational landscape of adenoid cystic carcinoma. Nat Genet (2013) 1.83
Methylation of TFPI2 in stool DNA: a potential novel biomarker for the detection of colorectal cancer. Cancer Res (2009) 1.80
Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease. J Clin Endocrinol Metab (2013) 1.76
Rising incidence of second cancers in patients with low-risk (T1N0) thyroid cancer who receive radioactive iodine therapy. Cancer (2011) 1.71
IDH mutation and neuroglial developmental features define clinically distinct subclasses of lower grade diffuse astrocytic glioma. Clin Cancer Res (2012) 1.61
Decision making in the management of recurrent head and neck cancer. Head Neck (2013) 1.31
Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor Decitabine. Oncotarget (2013) 1.31
Predictors of survival in mucosal melanoma of the head and neck. Ann Surg Oncol (2011) 1.29
5-azacytidine reduces methylation, promotes differentiation and induces tumor regression in a patient-derived IDH1 mutant glioma xenograft. Oncotarget (2013) 1.28
Phase II trial of temozolomide in patients with relapsed sensitive or refractory small cell lung cancer, with assessment of methylguanine-DNA methyltransferase as a potential biomarker. Clin Cancer Res (2012) 1.27
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY DISEASE STATE CLINICAL REVIEW: THE INCREASING INCIDENCE OF THYROID CANCER. Endocr Pract (2015) 1.22
Exomic sequencing of medullary thyroid cancer reveals dominant and mutually exclusive oncogenic mutations in RET and RAS. J Clin Endocrinol Metab (2012) 1.21
Genomic dissection of the epidermal growth factor receptor (EGFR)/PI3K pathway reveals frequent deletion of the EGFR phosphatase PTPRS in head and neck cancers. Proc Natl Acad Sci U S A (2011) 1.21
Radiation necrosis following treatment of high grade glioma--a review of the literature and current understanding. Acta Neurochir (Wien) (2011) 1.18
Valproic acid use during radiation therapy for glioblastoma associated with improved survival. Int J Radiat Oncol Biol Phys (2013) 1.16
MRI perfusion in determining pseudoprogression in patients with glioblastoma. Clin Imaging (2012) 1.13
Genomic dissection of Hurthle cell carcinoma reveals a unique class of thyroid malignancy. J Clin Endocrinol Metab (2013) 1.07
Biomarkers for detection and prognosis of breast cancer identified by a functional hypermethylome screen. Epigenetics (2012) 1.07
Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma. Neuro Oncol (2012) 1.04
Synchronous cancers in patients with head and neck cancer: risks in the era of human papillomavirus-associated oropharyngeal cancer. Cancer (2013) 1.04
The FAT epidemic: a gene family frequently mutated across multiple human cancer types. Cell Cycle (2013) 1.00
Driver mutations of cancer epigenomes. Protein Cell (2014) 0.98
Long-term regional control in the observed neck following definitive chemoradiation for node-positive oropharyngeal squamous cell cancer. Int J Cancer (2013) 0.96
Raynaud's phenomenon of the tongue. J Rheumatol (2013) 0.94
Genetic basis for clinical response to CTLA-4 blockade. N Engl J Med (2015) 0.94
Reconstruction of congenital microtia-atresia: outcomes with the Medpor/bone-anchored hearing aid-approach. Ann Plast Surg (2009) 0.91
Protein tyrosine phosphatase receptor delta acts as a neuroblastoma tumor suppressor by destabilizing the aurora kinase A oncogene. Mol Cancer (2012) 0.91
Abbreviated course of radiation therapy with concurrent temozolomide for high-grade glioma in patients of advanced age or poor functional status. J Neurooncol (2012) 0.89
Epigenetic therapy: use of agents targeting deacetylation and methylation in cancer management. Onco Targets Ther (2013) 0.88
Ischemic necrosis of the tongue in patients with cardiogenic shock. Laryngoscope (2010) 0.88
The familial Parkinson disease gene PARK2 is a multisite tumor suppressor on chromosome 6q25.2-27 that regulates cyclin E. Cell Cycle (2010) 0.86
Immunotherapy: The path to win the war on cancer? Cell (2015) 0.84
Ipilimumab and whole brain radiation therapy for melanoma brain metastases. J Neurooncol (2014) 0.82
Therapeutic targeting of tumor suppressor genes. Cancer (2014) 0.82
First bite syndrome: incidence, risk factors, treatment, and outcomes. Laryngoscope (2012) 0.81
Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses. Cell (2016) 0.80
Recent advances in radiation therapy. Am Fam Physician (2008) 0.80
Prevalence of occult nostril asymmetry in the oversized nasal tip: a quantitative photographic analysis. Arch Facial Plast Surg (2011) 0.80
Single-stage BAHA implantation in adults and children: is it safe? Otolaryngol Head Neck Surg (2008) 0.79
The protein tyrosine phosphatase receptor D, a broadly inactivated tumor suppressor regulating STAT function. Cell Cycle (2009) 0.79
14-3-3sigma and p21 synergize to determine DNA damage response following Chk2 inhibition. Cell Cycle (2009) 0.78
Reduced impact of nodal metastases as a prognostic factor for tonsil cancer in the HPV era. Eur Arch Otorhinolaryngol (2013) 0.78
MAPping the genomic landscape of low-grade pediatric gliomas. Nat Genet (2013) 0.78
Imaging after GliaSite brachytherapy: prognostic MRI indicators of disease control and recurrence. Int J Radiat Oncol Biol Phys (2009) 0.78
Temporal relationship of post-operative radiotherapy with temozolomide and oncologic outcome for glioblastoma. J Neurooncol (2013) 0.77
Medullary thyroid carcinoma: ethical issues for the surgeon. Ann Surg Oncol (2012) 0.77
Intracranial hemorrhage during GliaSite RTS manipulation in an anticoagulated patient. J Radiother Pract (2007) 0.75
Molecular mechanisms orchestrating cyclin stability. Cell Cycle (2014) 0.75
Blood clot cast of the tracheobronchial tree. ANZ J Surg (2010) 0.75
In reference to "Thyroid surgery: changing patterns of practice" and "Emerging trends in the performance of parathyroid surgery". Laryngoscope (2008) 0.75
High-resolution genomic analysis: the tumor-immune interface comes into focus. Genome Biol (2015) 0.75
Pathology quiz case 1: ameloblastic carcinoma. Arch Otolaryngol Head Neck Surg (2010) 0.75
Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses. Cell (2017) 0.75
Effects of various submucous resection techniques of septal cartilage on nasal tip projection. Int Forum Allergy Rhinol (2011) 0.75
Erratum: Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat Med (2017) 0.75
Cavernous hemangioma of the carotid sheath. Otolaryngol Head Neck Surg (2009) 0.75
Image of the month. Tertiary hyperparathyroidism after parathyroidectomy with autotransplantation. Arch Surg (2011) 0.75